Filing Details
- Accession Number:
- 0001209191-23-004871
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-25 17:50:27
- Reporting Period:
- 2023-01-23
- Accepted Time:
- 2023-01-25 17:50:27
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
25743 | Therapeuticsmd Inc. | TXMD | Pharmaceutical Preparations (2834) | 870233535 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1627810 | C Michael Donegan | 951 Yamato Road Suite 220 Boca Raton FL 33431 | Prin. Fin. And Acctg. Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-01-23 | 380 | $0.00 | 4,934 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2023-01-23 | 1,066 | $0.00 | 6,000 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2023-01-23 | 519 | $0.00 | 6,519 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2023-01-23 | 2,400 | $0.00 | 8,919 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-01-23 | 1,302 | $5.34 | 7,617 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-01-24 | 7 | $5.31 | 7,610 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Units | Disposition | 2023-01-23 | 380 | $0.00 | 380 | $0.00 |
Common Stock | Restricted Stock Units | Disposition | 2023-01-23 | 1,066 | $0.00 | 1,066 | $0.00 |
Common Stock | Restricted Stock Units | Disposition | 2023-01-23 | 519 | $0.00 | 519 | $0.00 |
Common Stock | Restricted Stock Units | Disposition | 2023-01-23 | 2,400 | $0.00 | 2,400 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | M | Direct | ||
0 | No | 4 | M | Direct | ||
0 | No | 4 | M | Direct | ||
0 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).
- The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of ranging from $5.32 through $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
- The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
- The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
- Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
- The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".